TCCA
TEAS CHANGE OF CORRESPONDENCE RECEIVED
04/16/2025
Back to search
Official data from USPTO
RECOMBUMIN
Did you know this trademark is already registered in United States?
Before investing in name, identity, and promotion, validate collision risk and registration strategy to avoid wasting time and budget.
Active USPTO registrationType: WordOffice: United States
Quick snapshot
RECOMBUMIN
ST13
US500000079345867Class
1, 5
Filing
79345867
Registration
7362015
Risk and opportunity diagnosis
Executive reading for naming, filing, and monitoring decisions.
USPTO status
Active USPTO registration
Case type
Application and registration
Recorded events
37
Latest update
05/08/2025
Trademark type
Word
Nice classes
1, 5
Filing date
05/26/2022
Registration date
04/23/2024
Expiration date
-
Complete case details
Structured fields from the responsible authority and the official record.
Status date
04/23/2024
Last transaction
05/08/2025
Responsible office
United States Patent and Trademark Office
Status code
700
Official register
Principal Register
Drawing code
4
Owner type
98
Owner location
GB
Examiner
PERKINS, ELLEN
Law office
M10
Current location
PUBLICATION AND ISSUE SECTION
Holders and representatives
Holders
Sartorius Albumedix Limited
Albumedix Ltd
Representatives
Karen Lim Fross Zelnick Lehrman & Zissu, P.C.
Technical classification
Nice Classes
Class 1Class 5
Vienna Codes
No Vienna codes available.
Goods and services
Class 1
Chemicals used in industryscience and for use in the manufacture of pharmaceuticals; chemical reagents other than for medical or veterinary purposes; diagnostic reagents and preparationsother than for medical or veterinary purposes; chemical excipients for use in the manufacture of pharmaceutical preparations; proteins for industrial purposes; recombinant human albumin for use as a stabilizer and excipient for industrial purposes and for use in the manufacture of cell culture mediacell and tissue storage and preservation media and for the manufacture of diagnostic imaging agents; cell culture reagents for scientific and research usechemical preservation reagents for scientific and research use; albumin for use in the manufacture of pharmaceutical productsvaccinescellular therapiesregenerative medicines and gene therapies; protein in raw material form for scientific and medical research
Class 5
Pharmaceuticals for the treatment or prophylaxis of viralbacterialfungalmetabolicendocrinemusculoskeletalcardiovascularcardiopulmonarygenitourinarysexual dysfunctiononcologicalhepatologicalhematologicalophthalmicrespiratorydigestiveneurologicalneurodegenerativeneuromuscularcentral nervous systemgastrointestinalhormonaldermatologicalpsychiatricimmune systemurinaryangiogenicgeneticmenopausalpain related diseases and disorders; pharmaceutical products and substances for the treatment or prophylaxis of viralbacterialfungalmetabolicendocrinemusculoskeletalcardiovascularcardiopulmonarygenitourinarysexual dysfunctiononcologicalhepatologicalhematologicalophthalmicrespiratorydigestiveneurologicalneurodegenerativeneuromuscularcentral nervous systemgastrointestinalhormonaldermatologicalpsychiatricimmune systemurinaryangiogenicgeneticmenopausalpain related diseases and disorders; albuminchemical preparationssynthetic peptidesprotein supplementsmonoclonalpolyclonalimmunologicalnative and recombinant antibodies for medical and veterinary usecells for medical and veterinary useviruseslive viruseslive- attenuated virusesattenuated virusesvirus-like particles and viral vectors for medical and veterinary usevaccinesgrowth factors for medical and veterinary useimmune modulators for medical and veterinary usemonoclonal antibodiesbiological tissue and tissue culturesrecombinant proteins for medical and veterinary usenucleic acid sequencesblood plasmablood components for medical and veterinary useall being for pharmaceutical use for the treatment or prophylaxis of viralbacterialfungalmetabolicendocrinemusculoskeletalcardiovascularcardiopulmonarygenitourinarysexual dysfunctiononcologicalhepatologicalhematologicalophthalmicrespiratorydigestiveneurologicalneurodegenerativeneuromuscularcentral nervous systemgastrointestinalhormonaldermatologicalpsychiatricimmune systemurinaryangiogenicgeneticmenopausalpain related diseases and disorders; reagents for medical use; diagnostic reagents for medical use; protein supplements for pharmaceutical purposes; albuminous preparations for medical or veterinary purposes; recombinant albumin for biological therapeutic purposes
Publications
History of USPTO decisions and trademark events.
37 publications found
ARAA
ATTORNEY/DOM.REP.REVOKED AND/OR APPOINTED
04/16/2025
REAP
TEAS REVOKE/APP/CHANGE ADDR OF ATTY/DOM REP RECEIVED
04/16/2025
CHAN
APPLICANT/CORRESPONDENCE CHANGES (NON-RESPONSIVE) ENTERED
04/16/2025
COAR
TEAS CHANGE OF OWNER ADDRESS RECEIVED
04/16/2025
ADCH
CHANGE OF NAME/ADDRESS REC'D FROM IB
04/11/2025
FINO
FINAL DECISION TRANSACTION PROCESSED BY IB
11/09/2024
FICS
FINAL DISPOSITION NOTICE SENT TO IB
10/23/2024
FIMP
FINAL DISPOSITION PROCESSED
10/23/2024
FICR
FINAL DISPOSITION NOTICE CREATED, TO BE SENT TO IB
07/24/2024
NRCC
NOTICE OF REGISTRATION CONFIRMATION EMAILED
04/23/2024
R.PR
REGISTERED-PRINCIPAL REGISTER
04/23/2024
NPUB
OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED
02/06/2024
PUBO
PUBLISHED FOR OPPOSITION
02/06/2024
GPNX
NOTIFICATION PROCESSED BY IB
02/05/2024
OPNS
NOTIFICATION OF POSSIBLE OPPOSITION SENT TO IB
01/17/2024
OP2R
NOTICE OF START OF OPPOSITION PERIOD CREATED, TO BE SENT TO IB
01/17/2024
NONP
NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED
01/17/2024
OPNX
NOTIFICATION OF POSSIBLE OPPOSITION - PROCESSED BY IB
01/13/2024
CNSA
APPROVED FOR PUB - PRINCIPAL REGISTER
12/31/2023
OPNS
NOTIFICATION OF POSSIBLE OPPOSITION SENT TO IB
12/27/2023
OPNR
NOTIFICATION OF POSSIBLE OPPOSITION CREATED, TO BE SENT TO IB
12/27/2023
TEME
TEAS/EMAIL CORRESPONDENCE ENTERED
11/03/2023
CRFA
CORRESPONDENCE RECEIVED IN LAW OFFICE
11/03/2023
TROA
TEAS RESPONSE TO OFFICE ACTION RECEIVED
11/03/2023
RFNT
REFUSAL PROCESSED BY IB
05/23/2023
RFCS
NON-FINAL ACTION MAILED - REFUSAL SENT TO IB
05/03/2023
RFRR
REFUSAL PROCESSED BY MPU
05/03/2023
NREP
NEW REPRESENTATIVE AT IB RECEIVED
04/02/2023
RFCR
NON-FINAL ACTION (IB REFUSAL) PREPARED FOR REVIEW
03/16/2023
CNRT
NON-FINAL ACTION WRITTEN
03/15/2023
DOCK
ASSIGNED TO EXAMINER
03/07/2023
NREP
NEW REPRESENTATIVE AT IB RECEIVED
01/29/2023
MAFR
APPLICATION FILING RECEIPT MAILED
08/02/2022
NWOS
NEW APPLICATION OFFICE SUPPLIED DATA ENTERED
07/29/2022
LIMI
LIMITATION FROM ORIGINAL APPLICATION ENTERED
07/27/2022
SDRC
SN ASSIGNED FOR SECT 66A SUBSEQ DESIG FROM IB
07/21/2022
Continuous trademark protection
Get notified about every new filing that threatens RECOMBUMIN or your mark.
Professional 24-month watch service: we monitor USPTO for you and alert you in time to oppose — before conflicts become losses.